Drugs / HAV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04135417 | Nov 2019 → May 2021 | end stage renal failure, kidney failure | Humacyte, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135417 ↗ |
| Modality | Other / unclassified | “The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease.” NCT04135417 ↗ |